(Q30448744)

21 June 2017

title

The role of SPARC in the TRAMP model of prostate carcinogenesis and progression (English)

1 reference

21 June 2017

1 reference

N Said

1

1 reference

21 June 2017

H F Frierson

2

1 reference

21 June 2017

D Chernauskas

3

1 reference

21 June 2017

M Conaway

4

1 reference

21 June 2017

K Motamed

5

1 reference

21 June 2017

D Theodorescu

6

1 reference

21 June 2017

language of work or name

English

0 references

publication date

13 July 2009

1 reference

21 June 2017

1 reference

21 June 2017

volume

28

1 reference

21 June 2017

issue

39

1 reference

21 June 2017

page(s)

3487-3498

1 reference

Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Aberrant promoter methylation of SPARC in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Development of UV-induced squamous cell carcinomas is suppressed in the absence of SPARC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

TGF-beta and BMP7 interactions in tumour progression and bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

The bone microenvironment in metastasis; what is special about bone?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Novel markers for poor prognosis in head and neck cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC enhances tumor stroma formation and prevents fibroblast activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Impact of differential cyclin D1 expression and localisation in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Molecular pathway for cancer metastasis to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Delineation of prognostic biomarkers in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Prostate cancer in a transgenic mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

31 March 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Molecular biology of bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

The current state of preclinical prostate cancer animal models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Normalization of the ovarian cancer microenvironment by SPARC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Morphogenesis of ductal networks in the mouse prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Aberrant methylation of SPARC in human lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Integrative molecular concept modeling of prostate cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Survey of differentially methylated promoters in prostate cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

Frequent inactivation of SPARC by promoter hypermethylation in colon cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.205

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.205

1 reference

Dimensions Publication ID

21 June 2017

1024186634

0 references

Fatcat ID

release_u7n5ik2jr5hddeaejdea2ko4ce

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u7n5ik2jr5hddeaejdea2ko4ce

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference